Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
H. Cortés-Funes(Centre Hospitalier René-Dubos), Miquel Tarón(Universitat Autònoma de Barcelona), Daniel A. Castellanos(Hospital Universitario 12 De Octubre), José María Viéitez(Hospital Universitario Central de Asturias), J.L. González-Larriba(Hospital Clínico San Carlos), Clara Mayo(USP Institut Universitari Dexeus), Carlos Camps(Universitat de València), F. Cardenal, Cristina Queralt(Universitat Autònoma de Barcelona), Á. Izquierdo(Catalan Institute for Water Research), Pilar Díz(Hospital de León), Carlos García Girón(Hospital General Yagüe), Pedro Méndez(Institut Català d'Ornitologia), Carlos Gegúndez Gómez(Hospital Xeral Calde), José Javier Sánchez(Research Institute Hospital 12 de Octubre), Rafael Rosell(Instituto Oncológico Dr. Rosell), Pedro Valero(Hospital Quirónsalud Sagrado Corazón), Teresa Morán(Institute of Agrifood Research and Technology), A. Velasco(Hospital Universitario de La Princesa), Vicente Alberola(Hospital Arnau de Vilanova), I. Maeztu
Cited by 231
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k